Chemours (NYSE:CC) Rating Lowered to “Strong Sell” at Zacks Research

Chemours (NYSE:CC) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued on Wednesday, Zacks reports.

Several other research analysts also recently commented on CC. JPMorgan Chase & Co. decreased their target price on shares of Chemours from $22.00 to $15.00 and set a “neutral” rating on the stock in a research note on Thursday, August 13th. Morgan Stanley set a $18.00 price target on shares of Chemours in a report on Monday, August 10th. Mizuho cut shares of Chemours from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $18.00 to $15.00 in a research report on Wednesday, October 14th. Barclays began coverage on shares of Chemours in a research note on Monday, October 12th. They set an “equal weight” rating and a $16.00 price objective for the company. Finally, The Goldman Sachs Group reiterated a “neutral” rating and set a $16.00 target price on shares of Chemours in a report on Friday, October 9th. Three research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $17.45.

Chemours Price Performance

Shares of Chemours stock opened at $12.77 on Wednesday. The company has a debt-to-equity ratio of 24.25, a current ratio of 1.81 and a quick ratio of 0.88. The business’s 50 day simple moving average is $14.02 and its two-hundred day simple moving average is $18.23. The stock has a market capitalization of $1.92 billion, a P/E ratio of -12.51 and a beta of 1.47. Chemours has a one year low of $10.44 and a one year high of $28.67.

Chemours (NYSE:CC) last released its quarterly earnings data on Monday, November 2nd. The specialty chemicals company reported $0.21 earnings per share for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.05). The company had revenue of $1.54 billion for the quarter, compared to analysts’ expectations of $1.53 billion. Chemours had a negative net margin of 2.64% and a positive return on equity of 76.52%. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period last year, the company posted $0.40 EPS. Analysts forecast that Chemours will post 0.81 EPS for the current year.

Insider Buying and Selling

In other Chemours news, insider Calderon Gerardo Familiar purchased 1,935 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The stock was bought at an average price of $15.53 per share, with a total value of $30,050.55. Following the completion of the purchase, the insider directly owned 58,547 shares of the company’s stock, valued at $909,234.91. The trade was a 3.42% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Denise Dignam purchased 3,378 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was acquired at an average cost of $14.95 per share, with a total value of $50,501.10. Following the purchase, the chief executive officer directly owned 339,916 shares of the company’s stock, valued at $5,081,744.20. This trade represents a 1.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.85% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Chemours

Several institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in shares of Chemours during the second quarter valued at about $477,769,000. Wolf Hill Capital Management LP purchased a new stake in Chemours in the second quarter worth about $59,698,056. Jefferies Financial Group Inc. lifted its holdings in Chemours by 251.8% in the third quarter. Jefferies Financial Group Inc. now owns 2,742,068 shares of the specialty chemicals company’s stock worth $37,210,000 after buying an additional 1,962,523 shares during the period. Bank of New York Mellon Corp bought a new stake in Chemours during the 2nd quarter valued at approximately $33,353,000. Finally, Bank of America Corp DE boosted its position in Chemours by 79.1% during the 1st quarter. Bank of America Corp DE now owns 1,317,003 shares of the specialty chemicals company’s stock valued at $29,014,000 after acquiring an additional 581,621 shares in the last quarter. 76.26% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Chemours

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours launched Faizeon two-phase liquid-cooling solutions for AI data centers, which the company says can improve efficiency and reduce water use. The launch gives investors a potential growth opportunity in a fast-growing market. Article: CC Launches Faizeon Cooling Solutions to Meet AI Data Center Demand
• Neutral Sentiment: Analyst views remain mixed: Barclays maintained a Hold rating, UBS kept Neutral while trimming its price target to $15, and Truist lowered its target to $18 but retained a Buy rating. Article: Barclays Keeps Their Hold Rating on Chemours
• Negative Sentiment: Multiple law firms publicized a securities class action against Chemours, with a December 7 lead-plaintiff deadline. The lawsuit alleges the company misrepresented 2026 EBITDA guidance by not accounting for distributor pre-buying that shifted about $65 million in Opteon refrigerant sales from 2026 into 2025. The allegations have not been proven, but the case adds legal and reputational risk. Article: SueWallSt Reminds Shareholders of Lead Plaintiff Deadline
• Negative Sentiment: Recent quarterly results also provide a headwind: Chemours reported EPS of $0.21, below the $0.26 consensus and down from $0.40 a year earlier, despite revenue modestly exceeding estimates. The earnings shortfall and concerns about refrigerant demand may be contributing to investor caution.

Chemours Company Profile

The Chemours Company (NYSE: CC) is a global chemistry company that develops and manufactures performance chemicals and advanced materials for industrial and consumer applications. The company serves customers in markets including automotive, construction, energy, electronics, healthcare, and general manufacturing.

Chemours operates through businesses focused on Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. Its products include titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper; refrigerants and related thermal-management solutions; and high-performance fluoropolymers and specialty materials sold under brands such as Teflon™, Viton™, and Nafion™.

Headquartered in Wilmington, Delaware, Chemours serves customers globally through manufacturing facilities, research and development operations, and commercial activities across North America, Latin America, Europe, and Asia-Pacific.